Episodes

  • EP 171: The past, present, and future of long-read sequencing with Jonathon Hill of Wasatch Biolabs

    EP 171: The past, present, and future of long-read sequencing with Jonathon Hill of Wasatch Biolabs
    Jan 23 2025
    This week on The Genetics Podcast, Patrick is joined by Jonathon Hill, associate professor at Brigham Young University and co-founder and VP of Wasatch Biolabs. Jonathan and Patrick discuss the power of long-read sequencing, how Wasatch Biolabs was created, and how Jonathon has fostered valuable collaborations between academic labs and Wasatch Biolabs.
    Show More Show Less
    35 mins
  • EP 170: Pan-European collaboration and dementia research with Angela Bradshaw, from Alzheimer Europe

    EP 170: Pan-European collaboration and dementia research with Angela Bradshaw, from Alzheimer Europe
    Jan 16 2025
    This week on The Genetics Podcast, Patrick is joined by Angela Bradshaw, Director for Research at Alzheimer Europe and honorary lecturer at the University of Glasgow. Patrick and Angela discuss how Alzheimer Europe partners in and support pan-European dementia research, the enormous heterogeneity of dementia and Alzheimer’s disease, the future of potential new gene therapies, and the critical role of advocacy organizations for patient communities.
    Show More Show Less
    42 mins
  • EP 169: Common variants in rare neurological diseases with Hilary Martin of the Wellcome Sanger Institute

    EP 169: Common variants in rare neurological diseases with Hilary Martin of the Wellcome Sanger Institute
    Jan 9 2025
    This week on The Genetics Podcast, we’re joined by Hilary Martin, Group Leader in Human Genetics at the world-renowned Wellcome Sanger Institute. Hilary and Patrick discuss her group’s work on neurodevelopmental conditions, the role of common genetic variants in rare disease, and how to untangle the impact of direct and indirect genetic influences on various traits. Find out more Nature paper: Examining the role of common variants in rare neurodevelopmental conditions https://www.nature.com/articles/s41586-024-08217-y Genes and Health Project https://www.genesandhealth.org
    Show More Show Less
    46 mins
  • EP 168: A world-first in RNA medicines with Erik Ingelsson, Chief Scientific Officer at Wave Life Sciences

    EP 168: A world-first in RNA medicines with Erik Ingelsson, Chief Scientific Officer at Wave Life Sciences
    Jan 2 2025
    Happy New Year! In our first episode of 2025, Patrick is joined by Erik Ingelsson, Chief Scientific Officer at Wave Life Sciences. Erik is also the formerr Senior Vice President of Target Discovery at GlaxoSmithKline and a former Professor at Stanford and Uppsala universities. Patrick and Erik discuss Wave’s world-first discovery in RNA editing therapies for Alpha-1 Antitrypsin Deficiency (AATD), Erik’s far-reaching career across academia, big pharma and biotech, and how to be a present parent in the thick of a thriving career.
    Show More Show Less
    38 mins
  • EP 167: Research Roundup with Dr. Veera: Wrapping up 2024 in four pioneering papers

    EP 167: Research Roundup with Dr. Veera: Wrapping up 2024 in four pioneering papers
    Dec 26 2024
    Join us as we welcome back Dr. Veera Rajagopal, a discovery scientist at Regeneron with an interest in human genetics and drug target discovery in neuroscience and psychiatry. If you’re a regular listener, you may be familiar with Veera’s quarterly appearances on the show, where Patrick and he discuss the latest developments in genetics, drug discovery, and precision medicine. Grab yourself a cup of something warm and tune in as Veera and Patrick close out 2024 with a wrap up covering: Population genomics programs New Alzheimer’s research The impact of genetics on menopause onset Newborn genetic screening Tune in now, and don’t forget to check out Veera’s substack, GWAS Stories, and his Twitter, @doctorveera.
    Show More Show Less
    1 hr and 16 mins
  • EP 166: Developing targeted therapies for ALS with Eric Green from Trace Neuroscience, Maze Therapeutics, and Stanford University

    EP 166: Developing targeted therapies for ALS with Eric Green from Trace Neuroscience, Maze Therapeutics, and Stanford University
    Dec 19 2024
    This week we’re joined by Eric Green, Founder and CEO of Trace Neuroscience, Co-Founder and Chief Scientific Officer at Maze Therapeutics, and Adjunct Clinical Assistant Professor at Stanford University School of Medicine. Eric and Patrick discuss Eric’s transition from cardiology to the world of entrepreneurship, the role of highly focused biotechs in creating precision therapies, and the development of high-impact gene therapies for people with amyotrophic lateral sclerosis (ALS).
    Show More Show Less
    43 mins
  • EP 165: Harnessing CRISPR and RNA editing to transform healthcare with Dr. Ness Bermingham

    EP 165: Harnessing CRISPR and RNA editing to transform healthcare with Dr. Ness Bermingham
    Dec 12 2024
    In this episode, we’re joined by Dr. Ness Bermingham, Operating Partner at Khosla Ventures and Chair of the Board at Korro Bio. A scientist-turned-biotech entrepreneur, Ness is passionate about the power of science to tackle some of healthcare’s biggest challenges. Ness co-founded Intellia Therapeutics, a leader in CRISPR gene editing, and Korro Bio, an innovator in RNA editing, driving breakthroughs that translate cutting-edge science into real healthcare solutions. With over 20 years of experience in biotech and healthcare, he’s played a vital role in shaping startups into companies that develop life-changing medicines. Tune in as we dive into Ness’s journey and his insights on innovation in biotech!
    Show More Show Less
    53 mins
  • EP 164: Groundbreaking advances in MMR-deficient rectal cancer, liquid biopsies, and precision oncology with Dr. Luis Diaz

    EP 164: Groundbreaking advances in MMR-deficient rectal cancer, liquid biopsies, and precision oncology with Dr. Luis Diaz
    Dec 5 2024
    Welcome back to The Genetics Podcast! Today, we’re joined by Dr. Luis Diaz, Head of the Division of Solid Tumor Oncology at Memorial Sloan Kettering and a White House Appointee to the National Cancer Advisory Board. Dr. Diaz’s career has been defined by his commitment to translating cutting-edge cancer genomics into clinical practice. In this episode, he and Patrick dive into his groundbreaking trial on mismatch repair (MMR)-deficient rectal cancer, along with his pioneering work on liquid biopsies, immunotherapies targeting tumors with microsatellite instability, and advancements in precision oncology. To learn more about Dr. Diaz and his work, visit his research page here: https://www.mskcc.org/research-areas/labs/luis-diaz.
    Show More Show Less
    47 mins